Compare KALV & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALV | QDEL |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2022 |
| Metric | KALV | QDEL |
|---|---|---|
| Price | $26.99 | $13.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.60 | $28.25 |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 07-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.35 |
| EPS | ★ N/A | N/A |
| Revenue | $50,000,000.00 | ★ $2,730,200,000.00 |
| Revenue This Year | $185.42 | $3.51 |
| Revenue Next Year | $59.23 | $3.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $9.92 |
| 52 Week High | $27.00 | $35.58 |
| Indicator | KALV | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.79 | 54.63 |
| Support Level | $14.22 | $10.39 |
| Resistance Level | N/A | $15.76 |
| Average True Range (ATR) | 0.03 | 1.04 |
| MACD | -0.23 | 0.19 |
| Stochastic Oscillator | 95.83 | 50.94 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.